Adenosine vs Diltiazem for Treatment of SVT in the ED

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department

NCT07086560

Supraventricular Tachycardia (SVT)

RECRUITING

The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot

NCT01480336

Arrhythmia

COMPLETED NA

Adenosin to Rapidly Reverse Left Ventricle Impairment in Takotsubo Syndrome

NCT02867878

Takotsubo Cardiomyopathy Takotsubo Syndrome

TERMINATED PHASE2

Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm

NCT00007605

Atrial Fibrillation Cerebrovascular Accident Death, Sudden

COMPLETED PHASE3

Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

NCT05391893

Atrial Fibrillation Atrial Flutter

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Supraventricular Tachycardia (SVT)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adenosine

Group Type ACTIVE_COMPARATOR

adenosine

Intervention Type DRUG

IV adenosine at standard doses for SVT (6 mg, 12 mg)

Diltiazem

Group Type ACTIVE_COMPARATOR

diltiazem

Intervention Type DRUG

IV diltiazem at standard doses for SVT (0.25 mg/kg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

adenosine

IV adenosine at standard doses for SVT (6 mg, 12 mg)

Intervention Type DRUG

diltiazem

IV diltiazem at standard doses for SVT (0.25 mg/kg)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult patients (18 years and older)
2. Diagnosis of acute, stable SVT in the emergency department

Exclusion Criteria

1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%)
4. Severe bronchoconstrictive lung disease
5. Prior hypersensitivity to study medication
6. Previously enrolled in pilot study
7. Pregnant
8. Incarcerated

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No